Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback